AI assistant
PFIZER INC — Director's Dealing 2019
Sep 12, 2019
29831_dirs_2019-09-12_ec6c7097-cabc-44b8-91c3-a8762744f0fa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: SpringWorks Therapeutics, Inc. (SWTX)
CIK: 0001773427
Period of Report: 2019-09-12
Reporting Person: PFIZER INC (10% Owner)
Reporting Person: Pfizer Ventures (US) LLC (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Junior Series A Convertible Preferred Stock | $ | Common Stock (978194) | Direct | ||
| Series A Convertible Preferred Stock | $ | Common Stock (3039051) | Direct | ||
| Series B Convertible Preferred Stock | $ | Common Stock (526602) | Direct |
Footnotes
F1: Each share of Junior Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Junior Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Junior Series A Convertible Preferred Stock has no expiration date. Such shares are held of record by Pfizer Inc. ("Pfizer").
F2: Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date. Such shares are held of record by Pfizer.
F3: Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer.
F4: Each Reporting Person disclaims ownership of securities held by each other Reporting Person, except to the extent of its respective pecuniary interest therein.